Neuropilins as potential biomarkers in hepatocellular carcinoma: a systematic review of basic and clinical implications
- Author:
Paula FERNÁNDEZ-PALANCA
1
;
Tania PAYO-SERAFÍN
;
Carolina MÉNDEZ-BLANCO
;
Beatriz SAN-MIGUEL
;
María J. TUÑÓN
;
Javier GONZÁLEZ-GALLEGO
;
José L. MAURIZ
Author Information
- Publication Type:Review
- From:Clinical and Molecular Hepatology 2023;29(2):293-319
- CountryRepublic of Korea
- Language:English
- Abstract: Hepatocellular carcinoma (HCC) is one of the most common and deadly cancers worldwide and is characterized by complex molecular carcinogenesis. Neuropilins (NRPs) NRP1 and NRP2 are the receptors of multiple proteins involved in key signaling pathways associated with tumor progression. We aimed to systematically review all the available findings on their role in HCC. We searched the Scopus, Web of Science (WOS), PubMed, Cochrane and Embase databases for articles evaluating NRPs in preclinical or clinical HCC models. This study was registered in PROSPERO (CRD42022349774) and include 49 studies. Multiple cellular and molecular processes have been associated with one or both NRPs, indicating that they are potential diagnostic and prognostic biomarkers in HCC patients. Mainly NRP1 has been shown to promote tumor cell survival and progression by modulating several signaling pathways. NRPs mainly regulate angiogenesis, invasion and migration and have shown to induce invasion and metastasis. They also regulate the immune response and tumor microenvironment, showing a crucial interplay with the hypoxia response and microRNAs in HCC. Altogether, NRP1 and NRP2 are potential biomarkers and therapeutic targets, providing novel insight into the clinical landscape of HCC patients.
